New application of CD44 plasmid

A plasmid-based technology, applied in recombinant DNA technology, introduction of foreign genetic material, blood/immune system cells using vectors, etc., can solve problems such as breast cancer recurrence and metastasis

Inactive Publication Date: 2015-10-07
天津市第四中心医院
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The existence of CSC is one of the most important factors affecting the treatment effect and prognosis of breast cancer. The current clinical radiotherapy and chemotherapy can only eliminate common breast cancer cells, while the r...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of CD44 plasmid
  • New application of CD44 plasmid
  • New application of CD44 plasmid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] 1 Materials and methods

[0021] 1.1 Main materials DMEM medium, fetal bovine serum, penicillin and streptomycin, lymphocyte separation medium were purchased from Tianjin Haoyang Biological Products Technology Co., Ltd.; B27 factor, recombinant epidermal growth factor (EGF), basic fibroblast growth factor (bFGF ) was purchased from PeproTech Company of the United States; granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4, (IL)-2, tumor necrosis factor (TNF)-α, interferon (IFN )-γ and monoclonal antibody CD3 were purchased from Gibco, USA; RNA extraction kits were purchased from Qiagen; RT-PCR kits were purchased from Takara; agarose gel recovery, small plasmid extraction, and large plasmid extraction kits were all purchased from Tiangen Biochemical Technology Co., Ltd. Breast cancer cell line MDA-MB-231 was purchased from ATCC.

[0022] 1.2 Method

[0023] 1.2.1 Preparation of subcultured cell culture medium of MDA-MB-231: DMEM 445ml, 10% f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides new application of a CD44 plasmid. The CD44 plasmid can be effectively used for enhancing the in-vitro damaging effect of DC-CIK on mammary cancer stem cells.

Description

technical field [0001] The present invention relates to a new application of CD44 plasmid. Background technique [0002] Breast cancer is the most common malignancy in women worldwide. A large number of evidences show that it is the existence of breast cancer stem cells (Breast Cancer Stem Cell, BCSC) that leads to its easy metastasis, recurrence and resistance to radiotherapy and chemotherapy. Adoptive cell immunotherapy (ACI), which has emerged in recent years, is a new therapy for tumors that are insensitive to radiotherapy and chemotherapy. It has broad clinical prospects and has received more and more attention. [0003] The existence of CSC is one of the most important factors affecting the treatment effect and prognosis of breast cancer. The current clinical radiotherapy and chemotherapy can only eliminate common breast cancer cells, while the remaining BCSCs that are resistant to radiotherapy and chemotherapy can still proliferate continuously, leading to breast can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/0784C12N5/0783C12N15/85A61P35/00
Inventor 孙雯雯
Owner 天津市第四中心医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap